BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

British Pharmaceutical Market to Reach $31.7 Billion by 2020, Forecasts GlobalData


9/24/2013 11:45:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 24 September 2013 - A growing disease burden, universal coverage and good access to healthcare facilities are boosting the UK healthcare market; but increasing use of generics and government cost-cutting measures to reduce expenditure are restricting further growth, says research and consulting firm GlobalData.

According to the company’s latest report*, the UK pharmaceutical market was worth $24 billion in 2012 and is forecast to reach $31.7 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 3.5%. The segments that dominated the market in 2012 were Central Nervous System (CNS) drugs, along with cardiovascular and respiratory system drugs.

The medical device market is also forecast to grow, from $12 billion in 2012 to $17.5 billion by 2020, at a CAGR of 4.8%. In 2012, the major market shares were ophthalmic devices ($1.4 billion), orthopedic devices ($1.4 billion), wound care management ($1.1 billion), cardiovascular devices ($1.1 billion) and drug delivery devices ($1 billion).

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “With the availability of reimbursement, advances in medical technology and growing disease awareness allowing for early diagnosis, the UK’s medical device market is expected to grow significantly in the near future.

“Furthermore, structural reforms in the healthcare system and sufficient infrastructure, in addition to easily accessible healthcare facilities and a straightforward reimbursement process, are ensuring a positive healthcare landscape in the UK.”

However, increasing generic substitution and cost-cutting measures adopted by the British government and the National Health Service (NHS) have had a negative impact on market growth. In 2013, the Department of Health announced plans to cut drug prices by 10–20% on approximately 10% of branded medicines not covered by the voluntary Pharmaceutical Price Regulation Scheme (PPRS).

“These price cuts will adversely affect the revenues of branded medicine manufacturers in the UK. What’s more, generics are priced lower than patented drugs, which saw a decrease in the overall value of the UK pharmaceutical market,” concludes Owide.

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

This report provides an analysis on the healthcare, regulatory and reimbursement landscape of the UK; it identifies the key trends in the healthcare market and provides insights on the demographic, regulatory and reimbursement landscape and healthcare infrastructure. Most importantly, this report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@globaldata.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES